Creative Medical reports wider Q2 loss as expenses rise
Creative Medical Technology Holdings posted a Q2 net loss of USD 1.51 million, widening from USD 1.23 million a year earlier.
Selling, general and administrative expense climbed 48% to USD 1.08 million, driven by higher marketing spend tied to a company-level campaign.
Research and development expense fell 8% to USD 459,200 as the CELZ-201 ADAPT trial moved into follow-up, partly offset by broader platform investment.
Other income rose to USD 50,913 from USD 30,217 on higher short-term investment balances, while no revenue was generated.
FDA cleared an ADAPT trial expansion in June to add patients with ongoing opioid use; cash and US Treasuries totaled USD 8.71 million at June 30.
CELZ•
